NKGN NKGEN BIOTECH
- 1.500
- +0.080+5.63%
- 1.520
- +0.020+1.33%
NKGEN BIOTECH News
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGen Biotech, Inc. (Nasdaq: NKGN) today announced an online publication, titled "Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity (SNK02) in Patients with Advanced Solid Tumors without Lymphodepletion" at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.
10-Q: Quarterly report
Top Midday Gainers
MultiMetaVerse Holdings (MMV) said Monday that it signed a non-binding term sheet to acquire 100% of Bowong Technology and its subsidiaries for an undisclosed amount. Shares surged 135% as intraday tr
Trending Stocks Today: MultiMetaVerse Soars 136.96%
May 20th - US stocks trending in regular trading hours.Gainers: $MultiMetaVerse(MMV.US)$ shoots up 136.96% to $1.4 with a turnover of $192.18 million. $GT Biopharma(GTBP.US)$ surges 150.32% to $7.81 w
Sector Update: Health Care Stocks Ease Monday Afternoon
Health care stocks were lower Monday afternoon with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB) rose
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share.
SCPX, XTIA and CRVO Among Mid-day Movers
Nasdaq Surges 100 Points; Wix.com Shares Jump Following Q1 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday.The Dow traded up 0.04% to 40,020.16 while the NASDAQ rose 0.64% to 16,792.13. The S&
PTC Therapeutics, Oragenics, GT Biopharma Among Healthcare Movers
Why NKGen Biotech Stock Is Moving Higher Monday
NKGen Biotech Inc (NASDAQ:NKGN) shares are trading higher Monday after the company's SNK01 NK Cell Therapy was cleared to begin a Phase 2 trial in Alzheimer's disease.What To Know: NKGen announced tha
NKGen Shares Soar After SNK01 Cleared for Phase 2
By Dean Seal Shares of NKGen Biotech jumped after the company was cleared to progress its SNK01 cell product for the treatment of Alzheimer's disease into its next phase of clinical development. The
Market-Moving News for May 20th
PTCT: 27% | PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluationNKGN: 81% | NKGen Biotech Announces Its Safety Review Committee Has Cleared Co.'s SNK01 T
NKGen Biotech Announces Its Safety Review Committee Has Cleared Co.'s SNK01 To Progress Into Phase 2 Development In Alzheimer's Disease
NKGen Biotech Announces Its Safety Review Committee Has Cleared Co.'s SNK01 To Progress Into Phase 2 Development In Alzheimer's Disease
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease
NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced that its Safety Review Committee has cleared the Company's cryopreserved autologous, expanded and enhanced SNK01 to progress into Phase 2 clinical development.
Market-Moving News for April 29th
TSLA: 14% | Tesla shares are trading higher on reports the company will partner with Baidu for mapping and navigation for Full Self-Driving in China.PHG: 46% | Philips shares are trading higher after
NKGen Biotech Announces FDA Clearance Of IND Application For SNK01 NK Cell Therapy in Parkinson's Disease
NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients with Parkinson's disease.The Company expects to initiate a Phase 1 clini
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersDeciphera Pharmaceuticals (NASDAQ:DCPH) stock rose 71.0% to $25.05 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Koninklijke Philips (NYSE
12 Health Care Stocks Moving In Friday's Intraday Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 61.4% to $1.17 during Friday's regular session. The company's market cap stands at $5.1 million. Agenus (NASDAQ:AGEN) shares rose 32.53% to $11.
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SANTA ANA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative
ING, PALI and FNCH Among Pre-market Losers
Analysis
Price Target
No Data
